看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。8 O1 s8 q+ z/ ]5 ]
" w3 C8 V' I0 V9 p
* L9 n" o1 h! f% K9 TCurrently available feasibility data for possible combination strategies. : |$ q% G4 T2 T8 m
————————————————————————————————8 l& u/ @* v' \$ I8 p5 `
Combination Feasibility according to preliminary data ) F% h) A! y( ~; D. [4 T& z; b' e
——————————————————————————————————
$ h# R/ n, J- v0 W, `- SBevacizumab + sorafenib Yes, reduced dose
* ~7 v& m6 P" B. ~3 ]/ L3 qBevacizumab + sunitinib† No ' \/ B6 {. [! j. |, J, w U$ a
Bevacizumab + temsirolimus Yes
& t& f6 a, E2 F# r" ^; |7 ~. e; o- SBevacizumab + everolimus Yes 4 F5 ]- n) p- X3 X" F6 e. |: p7 s. L
Sorafenib + sunitinib ?
: i$ B# K( _8 E: p9 A F6 ?Sorafenib + temsirolimus Yes, reduced dose
x; |; u% W( fSorafenib + everolimus Yes, reduced dose
& n% u9 I( |) z1 ]4 H" HSunitinib + temsirolimus† No , d7 ~( w6 o4 U( {3 F/ G$ a
Sunitinib + everolimus ?
' v& d% A; I" k; A% GTemsirolimus + everolimus ?
& C4 S* I2 m+ a# k3 V6 L+ G( U————————————————————* |2 e6 y+ M- t& Z# E ?
†Led to US FDA warning.
/ W! [. j( Q4 S7 \?: As yet unattempted combination. u6 p& M; [# f+ f+ u# N5 \; q
|